Evidence map›Paper›PMID 33753770›Full record

ArticleScientific reports2021

LLL12B, a small molecule STAT3 inhibitor, induces growth arrest, apoptosis, and enhances cisplatin-mediated cytotoxicity in medulloblastoma cells.

Xiang Chen, Li Pan, Jia Wei, Ruijie Zhang, Xiaozhi Yang, Jinhua Song, Ren-Yuan Bai, Shengling Fu, Christopher R Pierson, Jonathan L Finlay and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. STAT3 signaling inhibitors for cancer treatment.Trends in pharmacological sciences · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Xiang Chen *Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Li Pan *Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Jia WeiDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Ruijie ZhangDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Xiaozhi YangDepartment of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL, 32610, USA.
Jinhua SongDepartment of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL, 32610, USA.
Ren-Yuan BaiDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Shengling FuDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Christopher R PiersonDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, The Department of Pathology and Department of Biomedical Education and Anatomy, The College of Medicine, The Ohio State University, Columbus, OH, 43205, USA.
Jonathan L FinlayDivision of Hematology, Oncology and BMT, Department of Pediatrics, College of Medicine, The Research Institute At Nationwide Children's Hospital, The Ohio State University, Columbus, OH, 43205, USA.
Chenglong LiDepartment of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL, 32610, USA. lic@cop.ufl.edu.
Jiayuh LinDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. JLin@som.umaryland.edu.
University of Maryland, Baltimore · USUniversity of Florida · USThe Ohio State University · USJohns Hopkins University · US

Funding

A novel STAT3-selective inhibitor for medulloblastoma therapyR01NS087213 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI LI, CHENGLONG, LIN, JIAYUH · 2015 to 2020
$1.7M
NINDS NIH HHS R01 NS087213
6 · The paper itself

Abstract

Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor and an oncogene product, which plays a pivotal role in tumor progression. Therefore, targeting persistent STAT3 signaling directly is an attractive anticancer strategy. The aim of this study is to test the efficacy of a novel STAT3 small molecule inhibitor, LLL12B, in suppressing medulloblastoma cells in vitro and tumor growth in vivo. LLL12B selectively inhibited the induction of STAT3 phosphorylation by interleukin-6 but not induction of STAT1 phosphorylation by INF-γ. LLL12B also induced apoptosis in human medulloblastoma cells. In addition, LLL12B exhibited good oral bioavailability in vivo and potent suppressive activity in tumor growth of medulloblastoma cells in vivo. Besides, combining LLL12B with cisplatin showed greater inhibition of cell viability and tumorsphere formation as well as induction of apoptosis comparing to single agent treatment in medulloblastoma cells. Furthermore, LLL12B and cisplatin combination exhibited greater suppression of medulloblastoma tumor growth than monotherapy in vivo. The present study supported that LLL12B is a novel therapeutic agent for medulloblastoma and the combination of LLL12B with a chemotherapeutic agent cisplatin may be an effective approach for medulloblastoma therapy.

Indexed as

AnimalsAnthraquinonesAntineoplastic Combined Chemotherapy ProtocolsApoptosisCarcinogenesisCell Line, TumorCell MovementCell ProliferationCell SurvivalCisplatinHeterograftsHumansInterferon-gammaInterleukin-6MedulloblastomaMiceAnthraquinonesCisplatinIFNG protein, humanInterferon-gammaInterleukin-6LLL12 compoundSTAT1 protein, humanSTAT1 Transcription FactorSTAT3 protein, humanSTAT3 Transcription FactorSulfonamides

Identifiers

PMID33753770
PMCPMC7985203
OpenAlexW3138963314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.